ADMA Biologics, Inc. has grown revenue 35% a year over three years and 55% a year over five. Revenue growth, 3-year annual rate: +35% (Biotechnology median +17%). Revenue growth, 5-year rate: +55%, growth has slowed since the five-year average. Years of annual history on file: 19, FY2006 to FY2025, as filed.

ADMAADMA Biologics, Inc.

Healthcare

$10.36-35% 1Y

$10.36

$7.6052 weeks$20.38

Is it growing?

Mixed

Neither accelerating nor breaking down: operating margin widening (+11.3 points), but earnings down −19% year on year.

1 good, 1 to watch, 1 neutral

Revenue trend+8% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +55% a year.

Earnings trend−19% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction+11.3 points operating

Trailing-twelve-month operating margin, 44.0% now against 32.8% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearstop 3% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ADMA growing?

ADMA Biologics, Inc. has grown revenue 35% a year over three years and 55% a year over five.

+35%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +55%
Revenue growth, 5-year rate · +35% over three · growth has slowed since the five-year average
Years of annual history on file: 19
Years of annual history on file · FY2006 to FY2025, as filed

Details›